5 Treatment and prognostic factors in acute myeloid leukaemia

[1]  J. Bennett,et al.  A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). , 1995, Blood.

[2]  Stephen L. George,et al.  Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia , 1995 .

[3]  R. Bouabdallah,et al.  A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. , 1995, The New England journal of medicine.

[4]  P. Frenette,et al.  Granulocyte‐Macrophage colony stimulating factor (GM‐CSF) priming in the treatment of elderly patients with acute myelogenous leukemia , 1995, American journal of hematology.

[5]  F. Mandelli,et al.  Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. , 1995, The New England journal of medicine.

[6]  L. Bergmann,et al.  Interleukin-2 bolus infusion as late consolidation therapy in 2nd remission of acute myeloblastic leukemia. , 1995, Leukemia & lymphoma.

[7]  K. Saito,et al.  Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study. , 1995, Leukemia.

[8]  K. Cowan,et al.  Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. , 1995, Blood.

[9]  A. Bartolucci,et al.  A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial. , 1994, Leukemia.

[10]  P. Zinzani,et al.  FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias. , 1994, Leukemia.

[11]  R. Mayer,et al.  Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. , 1994, The New England journal of medicine.

[12]  R. Foà,et al.  Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. , 1994, Blood.

[13]  S. Feig,et al.  Treatment of advanced acute leukaemia with allogeneic bone marrow transplantation from unrelated donors , 1994, British journal of haematology.

[14]  J. Singer,et al.  Phase I study of recombinant interleukin-1 beta in patients undergoing autologous bone marrow transplant for acute myelogenous leukemia. , 1994, Blood.

[15]  E. Estey.  Use of colony-stimulating factors in the treatment of acute myeloid leukemia. , 1994, Blood.

[16]  W. Hiddemann,et al.  Modulation of intracellular metabolism of cytosine arabinoside in acute myeloid leukemia by granulocyte-macrophage colony-stimulating factor. , 1994, Leukemia.

[17]  S. Clark,et al.  Combinations of stem cell factor with other hematopoietic growth factors enhance growth and sensitivity to cytosine arabinoside of blast progenitors in acute myelogenous leukemia. , 1994, Cancer research.

[18]  J. Bennett,et al.  Treatment of Relapsed and Refractory AML with Mitoxantrone and Etoposide: A Study of the Eastern Cooperative Oncology Group , 1994 .

[19]  H. Prentice,et al.  The role of immunotherapy in bone marrow transplantation for acute myeloid leukemia. , 1994, Progress in clinical and biological research.

[20]  P. Sonneveld,et al.  Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON). , 1994, Leukemia.

[21]  B. Sikic,et al.  Clinical trials of modulation of multidrug resistance pharmacokinetic and pharmacodynamic considerations , 1993, Cancer.

[22]  P. Sonneveld,et al.  Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells. , 1993, Blood.

[23]  B. Simonsson,et al.  Treatment of minimal residual disease in myeloid leukemia--the immunotherapeutic options with emphasis on Linomide. , 1993, Leukemia & lymphoma.

[24]  W. Dalton,et al.  Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Sanz,et al.  Busulfan plus cyclophosphamide followed by autologous blood stem-cell transplantation for patients with acute myeloblastic leukemia in first complete remission: a report from a single institution. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Thompson,et al.  Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. , 1993, Bone marrow transplantation.

[27]  F. Appelbaum,et al.  Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  F. Mandelli,et al.  Pilot study of 5-aza-2'-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results. , 1993, Leukemia.

[29]  H. Prentice,et al.  Immunotherapy with interleukin 2 after ABMT in AML. , 1993, Bone marrow transplantation.

[30]  F. Appelbaum,et al.  A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study. , 1993, Blood.

[31]  W. van Putten,et al.  Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. , 1993, The New England journal of medicine.

[32]  M. Oken,et al.  Autologous bone marrow transplant in acute myeloid leukemia in first remission. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Szer,et al.  Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT. , 1993, Bone marrow transplantation.

[34]  H. Rugo,et al.  Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen , 1993 .

[35]  M. Amylon,et al.  Busulfan/etoposide--initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia. , 1993, Blood.

[36]  W. Anderson,et al.  Gene-marking to trace origin of relapse after autologous bone-marrow transplantation , 1993, The Lancet.

[37]  Z. Estrov,et al.  Role of interleukin-1 inhibitory molecules in therapy of acute and chronic myelogenous leukemia. , 1993, Leukemia & lymphoma.

[38]  H. Lazarus,et al.  Does in vitro bone marrow purging improve the outcome after autologous bone marrow transplantation? , 1993, Journal of hematotherapy.

[39]  R. Foà,et al.  Interleukin 2 treatment in acute myelogenous leukemia , 1993, Stem cells.

[40]  K. Sullivan,et al.  Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  L. Mangoni,et al.  Autologous bone marrow transplantation in acute myelogenous leukemia. , 1992, Leukemia.

[42]  T. Ahmed,et al.  Homoharringtonine is safe and effective for patients with acute myelogenous leukemia. , 1992, Leukemia.

[43]  M. Oken,et al.  Phase II clinical trial of carboplatin in relapsed and refractory leukemia. , 1992, Leukemia.

[44]  B. Sikic,et al.  Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  A. Rimm,et al.  Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. , 1992, Blood.

[46]  A. Bartolucci,et al.  A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  J. Laissue,et al.  Pharmacologic interactions between the resistance‐modifying cyclosporine sdz psc 833 and etoposide (VP 16–213) enhance In Vivo cytostatic activity and toxicity , 1992, International journal of cancer.

[48]  E. Solary,et al.  Surface markers in adult acute myeloblastic leukemia: correlation of CD19+, CD34+ and CD14+/DR--phenotypes with shorter survival. Groupe d'Etude Immunologique des Leucémies (GEIL). , 1992, Leukemia.

[49]  P. Thall,et al.  Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. , 1992, Blood.

[50]  M. Oken,et al.  Varying intensity of postremission therapy in acute myeloid leukemia. , 1992, Blood.

[51]  M. Schell,et al.  2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  P. Ritch,et al.  Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia , 1992 .

[53]  T. Tsuruo,et al.  Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. , 1992, Blood.

[54]  S. Nimer,et al.  Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  S. Nimer,et al.  Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. , 1992, Blood.

[56]  C. Schiffer,et al.  A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. , 1991, Blood.

[57]  R. Marcus,et al.  Successful treatment of acute myeloid leukemia beyond first remission with autologous bone marrow transplantation using busulfan/cyclophosphamide and unpurged marrow: the British autograft group experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  B. Sikic,et al.  Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. , 1991, Blood.

[59]  N. Ifrah,et al.  Double intensive consolidation chemotherapy in adult acute myeloid leukemia. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  Janice Gabrilove,et al.  Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia , 1991 .

[61]  D. Reece,et al.  High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults. , 1991, Blood.

[62]  M. Labopin,et al.  Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe : further evidence of the role of marrow purging by mafosfamide , 1991 .

[63]  R. Holle,et al.  Autologous blood stem cell (ABSCT) versus purged bone marrow transplantation (pABMT) in standard risk AML: influence of source and cell composition of the autograft on hemopoietic reconstitution and disease-free survival. , 1991, Bone marrow transplantation.

[64]  A. Ho,et al.  Etoposide in acute leukemia. Past experience and future perspectives , 1991, Cancer.

[65]  J. Bennett,et al.  Long term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group (ECOG) experience. , 1991, Leukemia research.

[66]  R. Day,et al.  Direct relationship between remission duration in acute myeloid leukemia and cell cycle kinetics: a leukemia intergroup study. , 1990, Blood.

[67]  H. Dohy,et al.  Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. , 1990, The New England journal of medicine.

[68]  D. Linch,et al.  High-dose chemotherapy and autologous bone marrow transplantation in acute myeloid leukemia , 1990 .

[69]  F. Baas,et al.  Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine. , 1990, Journal of the National Cancer Institute.

[70]  S. Vollset,et al.  Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  P. Desai,et al.  Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group. , 1990, Leukemia.

[72]  A. Rimm,et al.  Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.

[73]  J. Matthews,et al.  Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. , 1990, Blood.

[74]  J. Fay,et al.  High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  E. Estey,et al.  Response to salvage therapy and survival after relapse in acute myelogenous leukemia. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  S. Piantadosi,et al.  Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia , 1989 .

[77]  J. Reiffers,et al.  Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission: a prospective controlled trial , 1989, British journal of haematology.

[78]  K. Rai,et al.  The frequency of long‐term remission in patients with acute myelogenous leukaemia treated with conventional maintenance chemotherapy: a study of 760 patients with a minimal follow‐up time of 6 years , 1989, British journal of haematology.

[79]  E. Estey,et al.  Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia. , 1989, Leukemia.

[80]  Edward J. Lee,et al.  Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. , 1989, Blood.

[81]  W. Woods,et al.  Allogeneic bone marrow transplantation for acute nonlymphocytic leukemia in first remission. , 1988, Blood.

[82]  F. Appelbaum,et al.  Chemotherapy v marrow transplantation for adults with acute nonlymphocytic leukemia: a five-year follow-up , 1988 .

[83]  J. Bennett,et al.  Aclacinomycin A and etoposide (VP-16-213): an effective regimen in previously treated patients with refractory acute myelogenous leukemia. , 1988, Blood.

[84]  M. Oken,et al.  Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  Idarubicin in combination with etoposide and cytarabine in adult untreated acute non lymphoblastic leukemia. , 1987, European journal of cancer & clinical oncology.

[86]  K. Rai,et al.  Intensive postremission therapy in adults with acute nonlymphocytic leukemia using various dose schedules of ara-C: a progress report from the CALGB. Cancer and Leukemia Group B. , 1987, Seminars in oncology.

[87]  K. Miller,et al.  The predictive value of in-vitro techniques in acute non-lymphocytic leukemia. , 1987, Leukemia research.

[88]  O. Colvin,et al.  Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. , 1986, The New England journal of medicine.

[89]  W. Hiddemann,et al.  Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  H. Lazarus,et al.  High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  C. Begg,et al.  A randomized study of the efficacy of consolidation therapy in adult acute nonlymphocytic leukemia. , 1984, Blood.

[92]  T. Tsuruo,et al.  Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. , 1982, Cancer research.

[93]  N. Nissen,et al.  Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. , 1982, Blood.

[94]  J. Lefante,et al.  Treatment of acute myelogenous leukemia: Influence of three induction regimens and maintenance with chemotherapy or BCG immunotherapy , 1982, Cancer.

[95]  J. Smyth,et al.  Progress in Clinical and Biological Research , 1979 .

[96]  Josef Korinek,et al.  Proceedings of the American Society of Clinical Oncology , 1982 .